Delving into the Latest Updates on Kunshan Xinyunda Biotechnology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Nervous System Diseases

Other Diseases

Fusion protein

Small molecule drug

Antibody drug conjugate (ADC)

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	3
Immune System Diseases	3
Nervous System Diseases	2
Hemic and Lymphatic Diseases	2
Infectious Diseases	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Fusion protein	2
Small molecule drug	1
Antibody drug conjugate (ADC)	1

Top 5 Target	Count

FcRn(IgG receptor FcRn large subunit p51)	1
CD206(Macrophage mannose receptor 1)	1

I期剂量递增阶段主要目的：评价XYD-9668-198抗体偶联剂的安全性和耐受性；确定XYD-9668-198抗体偶联剂的最大耐受剂量(MTD)和II期试验推荐剂量(RP2D)。次要目的：考察XYD-9668-198抗体偶联剂及其代谢产物的药代动力学特征；评价XYD-9668-198抗体偶联剂的初步抗肿瘤活性；评估XYD-9668-198抗体偶联剂的免疫原性。II期剂量扩展阶段主要目的：评价XYD-9668-198抗体偶联剂的安全性和耐受性；评价XYD-9668-198抗体偶联剂的初步抗肿瘤活性。次要目的：考察XYD-9668-198抗体偶联剂及其代谢产物的药代动力学特征；评估XYD-9668-198抗体偶联剂的免疫原性。

[Translation]

The main objectives of the Phase I dose escalation phase are: to evaluate the safety and tolerability of the XYD-9668-198 antibody conjugate; to determine the maximum tolerated dose (MTD) and the recommended dose (RP2D) of the XYD-9668-198 antibody conjugate for Phase II trials. Secondary objectives: to investigate the pharmacokinetic characteristics of the XYD-9668-198 antibody conjugate and its metabolites; to evaluate the preliminary anti-tumor activity of the XYD-9668-198 antibody conjugate; and to assess the immunogenicity of the XYD-9668-198 antibody conjugate. The main objectives of the Phase II dose expansion phase are: to evaluate the safety and tolerability of the XYD-9668-198 antibody conjugate; to evaluate the preliminary anti-tumor activity of the XYD-9668-198 antibody conjugate. Secondary objectives: to investigate the pharmacokinetic characteristics of the XYD-9668-198 antibody conjugate and its metabolites; and to assess the immunogenicity of the XYD-9668-198 antibody conjugate.

Start Date05 May 2023

Sponsor / Collaborator

Kunshan Xinyunda Biotechnology Co., Ltd.

100 Clinical Results associated with Kunshan Xinyunda Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Kunshan Xinyunda Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Kunshan Xinyunda Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Kunshan Xinyunda Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 Jul 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

1

Phase 1

Phase 2

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

XYD-9668-198	Advanced Malignant Solid Neoplasm More	Phase 1/2
XYD-A01	Advanced Malignant Solid Neoplasm More	Phase 1
CN116804062 ( FcRn )Patent Mining	Nervous System Diseases More	Discovery
CN117327192 ( CD206 )Patent Mining	Nervous System Diseases More	Discovery